Pagoclone – (133737-32-3)

Pagoclone is an anxiolytic agent from the cyclopyrrolone family, related to drugs like zopiclone. It is a nonbenzodiazepine with a distinct chemical structure but similar effects to benzodiazepines.

Pagoclone binds with high affinity to the benzodiazepine binding site of human GABAA receptors containing α1, α2, α3, or α5 subunits. It acts as a partial agonist at α1-, α2-, and α5-containing receptors and a full agonist at α3-containing receptors.

It was investigated for treating stuttering and anxiety disorders but was never commercialized due to concerns about abuse potential and disappointing clinical trial results. Its effects can be reversed by flumazenil. Pagoclone’s long-term safety and abuse potential remain unassessed.

The above information is displayed for information purpose only, and has not been reviewed by EON nor does EON attests or validates the accuracy nor does it constitutes a recommendation or validation.

Sources:

https://en.wikipedia.org/wiki/Pagoclone
https://www.medchemexpress.com/Pagoclone.html
https://www.medkoo.com/products/10931
https://go.drugbank.com/drugs/DB04903